Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX43 (anti-PD-L1 ADC) in second-line or later recurrent/metastatic esophageal squamous cell carcinoma
CTR20244846Phase 2Active
- Sponsor
- Henlius
- Start
- Jan 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of HLX43 in Esophageal Squamous Cell Carcinoma (ESCC) and esophageal adenosquamous carcinoma (ASC) (2 cohorts), sponsored by Henlius. Started Jan 2025; status: active.
02
Drugs
HLX43
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)esophageal adenosquamous carcinoma (ASC)
Beyond the preview
Go deeper on CTR20244846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244846.